Alzheimer disease (AD) is a dementing illness with a mean duration of 8 to 10 years after the onset of memory impairment.
1 The course of AD is relentlessly progressive, although the rate of progression of AD is highly variable; the standard deviation of the yearly decline in many continuous cognitive and functional measures is of the same magnitude as the mean rate of decline. For example, AD is associated with a mean (SD) worsening of 3 (4) points per year on the Mini-Mental Status Examination (MMSE); 3 (3) points per year on the Blessed Dementia Scale (BDS), Information-Memory-Concentration subscale (BDS); 9 (9) points per year on the cognitive subscale of the AD Assessment Scale; and 10% (10%) decline per year on the Weintraub AD-specific Activities of Daily Living (ADL) Scale.
2-4 Clinical characteristics associated with more rapid decline in AD include early language impairment, psychiatric symptoms, and extrapyramidal features.
2 Male sex, high educational achievement, early age at disease onset, and the apolipoprotein E (
APOE) ε4 allele are inconsistently associated with more rapid rate of decline in AD.
2,5,6 However, these demographic, clinical, and genetic factors explain only a small fraction of the variability in rates of progression. We hypothesized that biochemical measures of plasma proteins or metabolites implicated in AD risk can predict progression and account for some of the variability in rate of decline.